PHRM1102 Week 1: National Medicines Policy, Regulation, Evidence, Scheduling, and PBS

Vocabulary practice cards covering National Medicines Policy, TGA and ARTG regulation, clinical trial phases, literature sources, scheduling under the SUSMP, and 2026 PBS thresholds.

National Medicines Policy (NMP)

An Australian policy framework aimed at improving health outcomes through equitable access to medicines and their safe, effective use.

Four Original Pillars of the NMP

The foundational components of the National Medicines Policy: equity of access; quality, safety and efficacy; quality use of medicines; and a viable and responsible medicines industry.

Equity of Access to Medicines

The pillar of the National Medicines Policy supported by Pharmaceutical Benefits Scheme (PBS) subsidies.

Quality Use of Medicines (QUM)

An NMP pillar exemplified by clinical interventions such as a pharmacist detecting duplicate paracetamol therapy and counselling the patient on safe dosing.

A Viable and Responsible Medicines Industry

The NMP pillar that addresses medicine manufacturing and supply sustainability.

2022 NMP Update Themes

Broad strategic themes emphasizing patient-centred care, collaboration, equitable access, and a sustainable medicines system.

Therapeutic Goods Administration (TGA)

The Australian regulatory agency whose primary role is to regulate therapeutic goods for quality, safety, and efficacy.

Therapeutic Goods Act 1989

The principal federal legislation regulating therapeutic goods in Australia.

Australian Register of Therapeutic Goods (ARTG)

The national register maintained by the TGA to record regulatory details of therapeutic goods, such as identifier, sponsor, ingredients, and registration status.

TGA Registration vs. PBS Subsidy

Two distinct regulatory and funding determinations: market approval and entry via TGA registration does not automatically grant PBS subsidy.

AUST L

A regulatory identifier for listed medicines on the ARTG, typically lower-risk products subject to standard listing requirements.

AUST L Clinical Efficacy Standard

The standard under which the TGA does not individually evaluate clinical efficacy prior to standard listing, though the sponsor must hold evidence supporting all permitted claims.

AUST R

A regulatory identifier for registered medicines evaluated through the TGA registration pathway, which includes individual assessment of evidence appropriate to the medicine.

AUST R Over-the-Counter Medicines

Non-prescription therapeutic goods that still require the formal registration pathway (AUST R) rather than listing, showing that not all AUST R medicines are prescription-only.

Product Information (PI)

Detailed, professional document providing uses, doses, contraindications, precautions, interactions, and adverse effects of a medicine.

Consumer Medicine Information (CMI)

Patient-friendly guidance designed to help consumers use a medicine safely and understand key safety information.

Preclinical Testing

The initial investigation stage that evaluates safety and biological properties in laboratory and animal models prior to human testing.

Phase I Clinical Trials

Early-stage human studies, usually conducted in small groups, focused primarily on safety, tolerability, and pharmacokinetics.

Phase II Clinical Trials

Clinical studies conducted in patient groups focusing on early efficacy, dose selection, and ongoing safety assessment.

Phase III Clinical Trials

Larger confirmatory trials evaluating efficacy and safety in broad patient populations, often compared against another active treatment or a placebo.

Phase IV Studies

Post-marketing surveillance studies monitoring real-world safety and effectiveness, including rare or delayed adverse effects.

Phase III Limitations for Rare ADRs

The inherent limitation wherein Phase III clinical trials may fail to detect rare adverse drug reactions due to restricted sample sizes and limited follow-up duration compared to widespread, long-term use.

Primary Literature

Original scientific research that presents newly collected empirical data, such as a randomised controlled trial.

Secondary Literature

Syntheses, analyses, or evaluations based on primary studies, such as a systematic review.

Tertiary Literature

Curated clinical reference summaries and guidance compilations, such as the Australian Medicines Handbook (AMH) or Therapeutic Guidelines.

Publication Bias

The systematic distortion in medical literature occurring when studies yielding positive or statistically significant results are more likely to be published than those with negative or null findings.

Limitations of Primary Clinical Research

Methodological weaknesses in original trials, including unrepresentative study samples, short duration of follow-up, conflicts of interest, and selective reporting of outcomes.

Australian Medicines Handbook (AMH) / MIMS

Primary clinical resources recommended for consulting medicine dosing, indications, and precautions.

Therapeutic Guidelines

A clinical reference resource specifically designed for providing disease-oriented clinical treatment recommendations.

PSA Self-Care Resources

Reference materials published by the Pharmaceutical Society of Australia providing patient-friendly self-care advice.

Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP)

The national legal standard (also known as the Poisons Standard) containing scheduling classifications that match access and professional oversight to public health risks such as toxicity, misuse, dependence, and monitoring needs.

Queensland Medicines and Poisons Legislation

Jurisdictional law, consisting of the Medicines and Poisons Act and Medicines Regulation, that establishes enforceable rules for prescribing, possession, storage, dispensing, and supply in Queensland.

Schedule 2 (S2)

A scheduling classification designating a Pharmacy Medicine supplied through a pharmacy.

Schedule 3 (S3)

A scheduling classification designating a Pharmacist Only Medicine, requiring professional pharmacist involvement in its supply.

Schedule 4 (S4)

A scheduling classification designating a Prescription Only Medicine.

Schedule 8 (S8)

A scheduling classification designating a Controlled Drug subject to heightened prescription, storage, and supply controls.

Morphine

An opioid analgesic classified under Schedule 8 (S8) as a Controlled Drug.

Perindopril

An ACE inhibitor classified under Schedule 4 (S4) as a Prescription Only Medicine.

Active Ingredient Scheduling Variations

The regulatory mechanism allowing products with identical active substances to be scheduled differently based on pack size, formulation, strength, and intended use.

Pharmaceutical Benefits Scheme (PBS)

An Australian Government program that subsidises eligible medicines to ensure timely, affordable, and equitable access for patients.

Pharmaceutical Benefits Advisory Committee (PBAC)

An independent statutory committee that evaluates clinical effectiveness, safety, comparative benefit, and cost-effectiveness when recommending medicines for PBS listing.

PBS Co-payment

The standard out-of-pocket patient contribution towards the cost of an eligible PBS-subsidised medicine.

2026 General PBS Co-payment Maximum

The standard maximum patient co-payment of $\text{AUD } \$25.00$ for general patients, excluding any applicable brand premiums or additional charges.

2026 Concessional PBS Co-payment Maximum

The maximum patient co-payment of $\text{AUD } \$7.70$ for concessional beneficiaries, excluding any applicable brand premiums or additional charges.

Under-Co-payment PBS Medicine

A PBS medicine whose total dispensed price is less than the statutory co-payment maximum, meaning the patient pays the lower applicable price.

PBS Safety Net

A protective mechanism designed to reduce medicine costs for individuals or families once their annual expenditure on eligible PBS medicines reaches a designated financial threshold.

2026 General PBS Safety Net Threshold

The annual cumulative expenditure threshold of $\text{AUD } \$1,748.20$ for general patients.

2026 Concessional PBS Safety Net Threshold

The annual cumulative expenditure threshold of $\text{AUD } \$277.20$ for concessional cardholders.

Brand Premium

An extra amount charged by a manufacturer for a specific brand of a medicine that is paid by the patient on top of the standard PBS co-payment.

Brand Premium Calculation Example

A transaction scenario where a general patient pays a $\$25.00$ co-payment plus a $\$6.00$ brand premium, resulting in a total payment of $\text{AUD } \$31.00$ (assuming no other charges or discounts).

PBS vs. Private Prescription

The distinction where a qualifying PBS prescription receives a Commonwealth government subsidy, whereas a private prescription receives no PBS financial subsidy.

PBS Early-Supply Rules

Specific regulatory provisions governing the early dispensing of repeat PBS prescriptions and dictating whether those supplies qualify for PBS subsidies and count toward the PBS Safety Net.

Duplicate Active Ingredient Check

A clinical safety screening performed by pharmacists to ensure patients are not taking multiple differently branded products containing the same drug, thereby preventing accidental overdosing.

Pharmacist Clinical Scope

Professional responsibilities beyond technical dispensing and labeling, including evaluating clinical appropriateness, intercepting medicine-related harm, counselling patients, and promoting quality use of medicines.